Patents and performance in the Japanese pharmaceutical industry: An institution-based view

Asia Pacific Journal of Management

Volumn 27, Issue 1, 2010, Pages 99-113

  Mahlich, Jörg C ^a  

^a Austrian Economic Chamber   (Austria)

Author keywords

Institutions; Japan; Patents; Performance; Pharmaceutical industry; Strategy

Indexed keywords

EID: 75849162541     PISSN: 02174561     EISSN: 15729958     Source Type: Journal    
DOI: 10.1007/s10490-008-9128-x     Document Type: Article

References (48)

1. Cockburn, I., & Griliches, Z. 1988. Industry effects and appropriability measures in the stock market's valuation of R& D and patents. American Economic Review, 78: 419-423.
2. Comanor, W. S., & Scherer, F. M. 1969. Patent statistics as a measure of technical change. Journal of Political Economy, 77: 392-398.
3. Czarnitzki, D., & Kraft, K. 2008. On the profitability of innovative assets. Applied Economics, forthcoming.
4. D'Aunno, T., Succi, M., & Alexander, F. 2000. The role of institutional and market forces in divergent organizational change. Administrative Science Quarterly, 45: 679-703.
5. DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. 2003. The price of innovation: New estimates of drug development costs. Journal of Health Economics, 22: 151-185.
6. Ernst, H. 2001. Patent applications and subsequent changes of performance: Evidence from time series cross section analyses on the firm level. Research Policy, 30: 143-157.
7. Fleischer, M. 1999. Innovation, patenting, and performance. Economie Appliquée, 52: 95-119.
8. Grabowski, H., Vernon, J., & DiMasi, J. 2003. Returns on research and development for 1990's new drug introductions. PharmacoEconomics, 20: 11-29.
9. Griliches, Z. 1981. Market value, R& D, and patents. Economic Letters, 7: 183-187.
10. Griliches, Z., Hall, B., & Pakes, A. 1991. R& D, patent, and market value revisited: Is there a second (technological opportunity) factor. Economics of Innovation and New Technology, 1: 183-201.
11. Gschwandtner, A., & Cable, J. 2008. On modeling the persistence of profits in the long run: An analysis of 156 US companies, 1950-1999. International Journal of the Economics of Business, 15: 245-263.
12. Haneda, S., & Odagiri, H. 1998. Appropriation from returns from technological assets and the values of patents and R& D in the Japanese high-tech firms. Economics of Innovation and New Technologies, 7: 303-321.
13. Hausman, J. A. 1978. Specification tests in econometrics. Econometrica, 46: 1251-1271.
14. Hiraki, T., Inoue, H., Ito, A., Kuroki, F., & Masuda, H. 2003. Corporate governance and firm value in Japan: Evidence from 1985-1998. Pacific Basin Finance Journal, 11: 239-265.
15. Huttin, C. 1995. The Japanese drug price policy: A new dynamic on price competition. Journal of Research in Pharmaceutical Economics, 4: 21-34.
16. IMS Health. 2006. IMS world review. Fairfield: Intercontinental Medical Statistics.
17. JPA. 2004. Annual report. Tokyo: Japan Pharmaceutical Association.
18. Kawaura, A., & La Croix, S. J. 1995. Japan's shift from process to product patents in the pharmaceutical industry: An event study of the impact on Japanese firms. Economic Inquiry, 33: 88-103.
19. Levin, R. C., Klevorick, A. K., Nelson, R. R., & Winter, S. G. 1987. Appropriating the returns from industrial research and development. Brooking Papers on Economic Activity, 3: 783-831.
20. Mahlich, J. 2007. The Japanese pharmaceutical industry in transition: Has higher research orientation resulted in higher market value. Asian Business and Management, 6: 75-94.
21. Mahlich, J., & Roediger-Schluga, T. 2002. New opportunities for Asian pharmaceutical firms. Asia Pacific Tech Monitor, Jan-Feb: 40-45.
22. Mahlich, J., & Roediger-Schluga, T. 2006. The determinants of pharmaceutical R& D expenditures: Evidence from Japan. Review of Industrial Organization, 28(2): 145-164.
23. Mansfield, E. 1986. Patents and innovation, an empirical study. Management Science, 32: 173-181.
24. Mansfield, E., Schwartz, M., & Wagner, S. 1981. Imitation costs and patents: An empirical study. Economic Journal, 91: 907-918.
25. Megna, P., & Klock, M. 1993. The impact of intangible capital on Tobin's q in the semiconductor industry. American Economic Review, 83(2): 265-269.
26. Moen, Ø. 1999. The relationship between firm size, competitive advantages and export performance revisited. International Small Business Journal, 18: 53-72.
27. Morck, R., Nakamura, M., & Shivdasani, A. 2000. Banks, ownership structure, and firms value in Japan. Journal of Business, 4: 539-567.
28. Mueller, D. 1986. Profits in the long run. Cambridge: Cambridge University Press.
29. Munshi, K., & Reich, M. 1994. Investment behavior and financial structure: The case of the Japanese pharmaceutical industry. Working paper no. 17-94, MIT Sloan School of Management.
30. Narin, F., Noma, E., & Perry, R. 1987. Patents as indicators of corporate technological strength. Research Policy, 16: 143-155.
31. Neumann, M., Böbel, I., & Haid, A. 1979. Profitability, risk and market structure in West German industries. Journal of Industrial Economics, 27: 227-242.
32. Neumann, M., Böbel, I., & Haid, A. 1981. Market structure and the labour market in West German Industries-a contribution towards interpreting the structure performance relationship. Journal of Economics, 41: 97-109.
33. Nightingale, P. 2000. Economies of scale in experimentation: Knowledge and technology in pharmaceutical R& D. Industrial and Corporate Change, 9: 315-359.
34. North, D. 1990. Institutions, institutional change, and economic performance. Cambridge: Cambridge University Press.
35. Oliver, C. 1991. Strategic responses to institutional processes. Academy of Management Review, 16: 145-179.
36. Pakes, A. 1985. On patents, R& D, and the stock market rate of return. Journal of Political Economy, 93: 390-409.
37. Pakes, A., & Shankerman, M. 1984. The rate of obsolescence of patents, research gestation lags, and the private rate of return to research resources. In Z. Griliches (Ed.). R& D, patents, and productivity: 455-503. Chicago: University of Chicago Press.
38. Peng, M. W. 2002. Towards an institution based view of business strategy. Asia Pacific Journal of Management, 19: 251-267.
39. Peng, M. W. 2003. Institutional transitions and strategic choices. Academy of Management Review, 28: 275-296.
40. Peng, M. W., Wang, D., & Jiang, Y. 2008. An institution-based view of international business strategy: A focus on emerging markets economies. Journal of International Business Studies, 29: 599-608.
41. PhRMA. 2003. Industry profile. Washington, DC: Pharmaceutical Research and Manufacturers of America.
42. Rajan, R. G. 1992. Insiders and outsiders: The choice between informed and arm's-length debt. Journal of Finance, 47: 1367-1400.
43. Scherer, F. M. 1965. Corporate inventive output, profits and growth. Journal of Political Economy, 73: 290-297.
44. Shapiro, D. M., & Switzer, L. N. 1993. The stock market response to changing drug patent legislation: The case of compulsory licensing in Canada. Managerial and Decision Economics, May/June: 247-261.
45. Sharpe, S. A. 1990. Asymmetric information, bank lending and implicit contracts: A stylized model. Journal of Finance, 45: 1069-1087.
46. Williamson, O. 1985. The economic institutions of capitalism. New York: Free Press.
47. Yafeh, Y., & Yosha, O. 2003. Large shareholders and banks: Who monitors and how. Economic Journal, 113: 128-146.
48. Zajac, E., Kraatz, M., & Bresser, R. 2000. Modeling the dynamics of strategic fit. Strategic Management Journal, 21: 429-454.